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I. INTRODUCTION 
[1]  Perhaps nothing permeates modern American society as much as 
prescription drugs.  Evidence of this exists not just in television and 
magazine ads extolling the promises of Viagra and Nexium, but also in a 
few statistics.  First, forty-six percent of Americans use at least one 
prescription drug daily.1  Further, in 2001, 3.1 billion prescriptions were 
issued in the United States at a cost of $132 billion.2  That amount is 
projected to increase to $414 billion by 2014.3  Such numbers explain the 
intensity of the recent political and legal debates surrounding prescription 
drugs, such as the importation of American pharmaceuticals from Canada 
and the issuance of prescriptions online without visiting a physician.4  
During the 2004 presidential campaign, President Bush touted his 
Medicare Modernization Act, a significant component of which concerned 
                                                 
* Jeff Todd is a third-year student at the University of Texas School of Law. A former 
professor of professional and technical communication, he will clerk at the Supreme 
Court of Texas before practicing in the Orange County, California office of Gibson, 
Dunn & Crutcher. He would like to thank Ron Woessner at ZixCorp for the opportunity 
to do this research. 
1 Greg Critser, One Nation, Under Pills, L.A. TIMES, Dec. 15, 2002, at M.6, available at 
http://www.namiscc.org/News/2003/Winter/PharmaceuticalStatistics.htm. 
2 Id. 
3 Id. 
4 See, e.g., Ronald L. Scott, Cybermedicine and Virtual Pharmacies, 103 W. VA. L. REV. 
407, 410-11, 421 & 482-83 (2001). 
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coverage of prescription drugs for senior citizens.5  On the business front, 
the issue most in the news is the high cost of brand-name pharmaceuticals 
compared to generics, and the high profit margin of pharmaceutical 
companies.6  
 
[2]  Another issue that does not receive the same headlines but has an 
enormous impact upon the delivery of health care is the increasing 
incorporation of high technology into the writing of prescriptions, more 
commonly referred to as electronic prescribing, or e-prescribing.  The 
nation’s 473,000 office-based physicians write the bulk of those 3.1 billion 
prescriptions, which somehow need to get from the physician to the 
pharmacy.7  Increasingly, more and more physicians are choosing to 
transmit their prescriptions electronically.8  Numerous e-prescribing 
system providers ranging from A (A4 Health Systems) to Z (ZixCorp) 
have fueled this growth, including SureScripts, which certifies retail 
pharmacies for receipt of transmissions and functions as a sort of technical 
distributor for e-prescribing.9  Despite initial implementation costs, e-
prescribing has the potential to reduce health care costs by improving 
efficiency, security, and patient safety.10  
 
[3]  Although much potential exists, the legal environment within this field 
presents numerous challenges.  The first of these challenges is the 
inconsistency in regulatory schemes.  The transmission of prescriptions is 
regulated by state law, and there are currently fifty different approaches, 
                                                 
5 Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 42 
U.S.C.A. § 1395w-101 (Sup. 2005). 
6 See, e.g., Thomas B. Leary, Antitrust Issues in the Settlement of Pharmaceutical Patent 
Disputes, Part II, 34 J. HEALTH L. 657, 661 (2001). 
7 See Joseph Goedert, Electronic Prescribing: Is It Just What the Doctor Ordered?, 
HEALTH DATA MGMT., June 2002, available at 
http://www.healthdatamanagement.com/HDMSearchResultsDetails.cfm?DID=12100. 
8 Compare id. (writing that e-prescribing increased from two to four percent of physicians 
in 2000 to six percent in 2001), with Ken Terry, Expanding Clinical Connections: 
Prescriptions, MED. ECON., Oct. 8, 2004, available at 
http://www.memag.com/memag/article/articleDetail.jsp?id=127292 (claiming that, by 
2004, e-prescribing was as high as eighteen percent). 
9 SureScripts, About SureScripts, http://www.surescripts.cm/coBack.htm (last visited 
April 5, 2006). 
10 E.g., Michelle Stowell, Transmitting Prescriptions Electronically: A Benefit or a 
Burden?, 32 MCGEORGE L. REV. 742, 750 (2001); Terry, supra note 8. 
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ranging from a lack of recognition of e-prescriptions to language that 
specifies technical standards and tries to accommodate trends.11  Because 
controlled substances are regulated by the Drug Enforcement 
Administration, federal law transcends state.12  Unfortunately, the DEA 
has not yet promulgated regulations for e-prescribing, so the states differ 
in their interpretation of the acceptability of electronic transmission of 
prescriptions for controlled substances.13  This uncertainty is heightened 
by the legislative process and regulatory language, neither of which can 
adequately account for the rapid evolution of the technologies involved in 
e-prescribing.14  Even political pressures come into play, such as the 
requirement in the Medicare Modernization Act for an e-prescribing 
technical standard by 2008.15  
 
[4]  These legal issues are a pressing concern as e-prescribing emerges as 
an increasingly important part of health care.  Attorneys for the companies 
that create and maintain these systems, for the doctors and pharmacists 
who use these systems, for the agencies that regulate these systems, and 
for the managed care and insurance providers that can reduce costs with 
these systems must stay abreast of a legal environment framed by 
uncertainty, conflict, and rapid change.  Although some recent legal 
scholarship has dealt with e-prescribing, the focus has been on the impact 
to federal law, such as HIPAA and E-Sign, or on practices that violate 
existing laws, such as ordering drugs without a prescription via the 
                                                 
11 Compare 49 PA. CODE § 27.20 (2005) (allowing for facsimile transmission of 
prescriptions but making no mention of electronically-generated prescriptions), with 105 
MASS. CODE REGS. 721.030 (2004) (providing precise standards for electronic technical 
security and e-signatures and accommodating potential changes to federal law regarding 
controlled substances). 
12 See 21 C.F.R. §§ 1300 – 1316 (2005). 
13 Compare 22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (allowing Schedule III-V 
substances to be transmitted electronically), with Memorandum from William Black, 
Wis. Dep’t of Reg. & Licensing, to Wis. Pharmacy Examining Bd. (Mar. 16, 2004), 
available at http://drl.wi.gov/boards/phm/pap/RXSignatures3-16-04.pdf (last visited 
January 8, 2005) (interpreting federal regulations as requiring electronically-generated 
prescriptions for Schedule III-V substances to be received via facsimile equipment and 
then orally verified with the prescriber). 
14 Marsha N. Cohen, RX by Email—Bad Medicine for a Chronic Rulemaking Illness, 
ADMIN. & REG. L. NEWS 10, 11 (Fall 2003). 
15 42 U.S.C.A. § 1395w-104(e) (Supp. 2005).
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Internet.16  As Ridgely and Greenberg point out in their article, however, 
those who undertake e-prescribing ventures must understand statutes and 
regulations that vary widely from state to state.17  This essay will explore 
the e-prescribing laws of the three most populous states:  California, 
Texas, and New York, as well as the DEA regulations that overlay state 
law to uncover the most typical legal problems encountered with the 
implementation and use of e-prescribing systems.  It will then offer ways 
to avoid, account for, or even change these problems.  First, though, it will 
examine e-prescribing in general and the impact of e-prescribing systems. 
 
II. E-PRESCRIBING IN GENERAL 
A. TRADITIONAL VERSUS E-PRESCRIBING 
Traditional Prescription Methods and Their Drawbacks 
[5]  Most people are familiar with the traditional methods for getting and 
filling a prescription.  A patient must first visit a physician, who after an 
examination determines whether certain medications are necessary for 
treatment.  The physician then writes the medication order on a 
prescription pad for the patient to deliver to the pharmacy, or the physician 
personally phones the order into the pharmacy or, in more recent times, 
sends it by facsimile.18  The patient then visits the pharmacy, either to pick 
up an order sent by phone or fax, or to present the prescription form to a 
pharmacist for filling.  
 
[6]  These traditional methods present several problems.  First, they are 
inefficient because of time wasted transcribing information for oral orders, 
re-entering data required for state and federal reporting, and calling 
                                                 
16 M. Susan Ridgely & Michael D. Greenberg, Pharmacy, Facsimile, and Cyberspace: 
An Examination of Legal Frameworks for Electronic Prescribing, 13 ALB. L.J. SCI. & 
TECH. 1 (2002); Scott, supra note 4. 
17 Ridgely & Greenberg, supra note 16, at 40-41. 
18 In many states, prescriptions for some controlled substances require a special form 
printed and distributed by the state for security and tracking purposes. See, e.g., N.Y. 
PUB. HEALTH LAW § 3332(2) (Consol. 2005); CAL. HEALTH & SAFETY CODE § 11161.5 
(West 2005). 
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doctors to clarify illegible handwriting.19  This inefficiency increases the 
labor costs for both doctors’ offices and pharmacies.20  It also wastes the 
patient’s time because of the delay between presenting and filling a 
written order.21  Other major concerns about traditional methods include 
potential medication errors due to illegible handwriting, the need to 
transcribe prescriptions multiple times, and possible adverse drug 
interactions.22   Medication errors arising from the traditional methods of 
prescribing medication lead not only to wasted time and extra hospital 
visits, they cause an estimated 7,000 deaths annually.23  
 
E-Prescribing and Its Perceived Drawbacks 
 
[7]  E-prescribing is “the use of an automated data entry system to 
generate a prescription, rather than writing it on paper.”24  In many ways, 
the core process is the same: the patient visits a physician, who, following 
an examination, determines if medications are necessary for treatment, and 
then writes a prescription.25  The key difference is the manner of 
transmitting the prescription: in e-prescription, the physician generates the 
prescription using a computer or a hand-held device such as a Blackberry, 
then transmits the prescription to an appropriate pharmacy.  Several 
companies offer software and related services that allow physicians to e-
prescribe by, for example, using a stylus or mouse to point and click his or 
her way through the patient’s record and to select the appropriate 
                                                 
19 Stowell, supra note 10, at 747. 
20 One doctor estimated that by switching from traditional methods to e-prescribing, his 
practice saved at least fifteen minutes of nurse overtime per day, and daily calls from 
pharmacies dropped from twenty to two, which translated to about $11,000 in one year.  
Terry, supra note 8. 
21 Stowell, supra note 10, at 747. 
22 Id. 
23 Id. at 742. 
24 Ridgely & Greenberg, supra note 16, at 3 (quoting Peter Kilbridge, E-Prescribing, I-
HEALTH REPORTS 5, Nov. 2001, 
http://www.chcf.org/documents/ihealth/Eprescribing.pdf). 
25 E-Prescribing could provide a means for obtaining and filling prescriptions without any 
patient-doctor face-to-face interaction.  Barbara J. Williams, On-Line Prescriptions and 
Drug Sales: An Overview of Emerging Issues, 1 HOUS. J. HEALTH L. & POL'Y 147, 147–
48 (2001).  However, many states explicitly forbid dispensing drugs based on a 
prescription where no valid patient-physician relationship exists, such as when the only 
interaction has been via the Internet.  See, e.g., 22 TEX. ADMIN. CODE § 291.34 (b)(1)(B) 
(LEXIS 2004).  
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medication.26  After the doctor generates an electronic prescription, e-
prescription software routes the prescription through the provider’s secure 
server to the pharmacy (and even the patient’s insurance provider, if so 
desired), where the prescription arrives as either electronic data or as a 
printed fax.27  In this way, e-prescription software is able to automatically 
create and store electronic records for the physician, the pharmacy, and 
even the insurance provider.28
 
[8]  As with any new technology, there are some concerns about the 
limitations and shortcomings of e-prescription technology.  For example, 
electronic systems that transmit data over the Internet are susceptible to 
interference by computer hackers.29  One possible consequence of hacker 
interference is diversion, whereby hackers use the system to illegally 
acquire prescription drugs by simulating authentic prescriptions.30 
Another possible consequence is access to confidential information.  Since 
patient data accompanies the e-prescription, patients could be less likely to 
provide their physicians with important private information for fear of it 
being intercepted by hackers.31  Another concern about e-prescriptions is 
that these electronic systems will be inefficient since pharmacists may be 
required to reduce to writing all electronically transmitted prescriptions for 
record-keeping purposes.32  Finally, high technology often means high 
cost, and not only do e-prescription systems require start-up costs and 
                                                 
26 Aside from companies such as Allscripts and ZixCorp, which are major providers of e-
prescription software and services, at least twenty-five different companies and 
organizations have some type of e-prescribing system.  SureScripts, supra note 9.  
27 See, e.g., Kilbridge, supra note 24, at 10.  For pharmacies that have neither fax nor 
electronic capability, the physician’s office could simply print the prescription for the 
patient, who then takes the script to the pharmacy in person. 
28 The various e-prescribing system providers’ websites provide more thorough 
descriptions of this process. See, e.g., PocketScript, ZixCorp, 
http://www.zixcorp.com/caredel/eprescribing.php (last visited Jan. 17, 2006).   
29 In an attempt to thwart hackers, one e-prescription service has licensed biometrics 
technology to ensure that the user of its e-prescription service is a licensed physician or 
pharmacist.  Steve Gold, Site Employs Biometrics for E-Prescription Security, 
COMPUTERUSER.COM, Apr. 18, 2000,  
http://www.computeruser.com/news/00/04/18/news6.html. 
30 Stowell, supra note 10, at 743, 748. 
31 Id. at 749. Of course, hacker access to a patient’s personal information creates the 
potential for identity theft. 
32 Id. at 746.  Some states require pharmacies to maintain hard copies of prescriptions for 
a specific amount of time for, among other reasons, law enforcement.  Id. 
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ongoing service fees for physicians and pharmacies, but also state officials 
may experience increased regulatory and enforcement costs.33   
 
B. THE BENEFITS OF E-PRESCRIBING FAR OUTWEIGH THE 
DRAWBACKS 
 
[9]  These fears may have seemed reasonable a decade ago, but 
advancements in technology and changes in the law have rendered them 
virtually null.  E-prescribing is not only more secure than traditional 
methods, it can increase efficiency and lower costs.34  Although the 
benefits are separated for convenience, note that they actually interrelate.  
For example, improved efficiency leads to lower physician and pharmacy 
costs and to fewer patient medical errors; fewer medical errors leads to 
reduced insurance costs as well as less medical provider liability.  
 
Increased Security 
 
[10]  Two changes have made e-prescribing more secure than traditional 
methods regarding patient confidentiality and diversion.  First, anyone 
who handles patient information—health care professionals, e-prescribing 
system providers, and insurance companies—must now meet HIPAA 
standards for confidentiality and security.35  Second, improvements in 
technology—such as minimum 128-bit encryption, passwords to log in to 
the systems, and automatic log-outs for periods of inactivity—have made 
interception more difficult and therefore less likely.36  Although dedicated 
hackers can still intercept electronic data, consider that thieves can more 
easily steal and forge prescription pads.37
 
 
 
                                                 
33 Id. 
34 See EHEALTH INITIATIVE, ELECTRONIC PRESCRIBING: TOWARD MAXIMUM VALUE AND 
RAPID ADOPTION 73-74 (2004), 
http://www.ehealthinitiative.org/assets/documents/eHIFullReport-
ElectronicPrescribing2004.pdf. 
35 Health Insurance Portability & Accountability Act of 1996, Pub. L. No. 104-191, 110 
Stat. 1936 (codified as amended in scattered sections of 45 C.F.R.). 
36 See PocketScript, supra note 28. 
37 EHEALTH INITIATIVE, supra note 34, at 73. 
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Better Patient Care 
 
[11]  E-prescribing can improve the effectiveness of health care by 
reducing errors.  For example, the elimination of hand-written 
prescriptions and transcriptions by office staff reduces errors caused by 
illegible writing or incorrect transcribing.38  Also, e-prescribing systems 
allow easy access to patient records and to computerized drug formularies, 
and they display warnings to the physician about patient allergies and 
adverse drug interactions.39  These factors can significantly reduce the 
estimated 2.1 million adverse drug events that lead to 190,000 
hospitalizations and thousands of deaths each year. 40
 
Greater Efficiency and Reduced Costs for Physicians and Pharmacists 
 
[12]  This decrease in medication errors is the result of an increase in 
efficiency.  E-prescribing increases efficiency because the data needs to be 
entered only once, eliminating transcriptions by nursing and secretarial 
staff and reducing the need for call backs since nothing is handwritten.41  
Further, the pharmacy can fill the order before the patient arrives, saving 
the patient time.42  Because the information is already stored 
electronically, refills are easier for all parties involved.43   
 
[13]  This increase in efficiency means a reduction in labor and costs for 
physician offices and pharmacies.  For example, reductions in callbacks 
from pharmacies saved one four-doctor office about $11,000 in overtime 
pay to nurses in one year.44  Fewer call-backs, the elimination of 
transcriptions, and shortened refill times saved one eight-doctor office 
about 3,000 total hours in one year.45  Even with initial start-up costs and 
                                                 
38 Stowell, supra note 19 at 747. 
39 Terry, supra note 8. 
40 EHEALTH INITIATIVE, supra note 34, at 28. 
41 Stowell, supra note 19 at 747. 
42 Id. 
43 Terry, supra note 8. 
44 Id. 
45 Jack Beaudoin, Study: E-Prescribing Cuts Labor Costs by 50 Percent, HEALTHCARE IT 
NEWS, Sept. 7, 2004, 
http://www.healthcareitnews.com/NewsArticleView.aspx?ContentID=1464. 
8 
Richmond Journal of Law & Technology Volume XII, Issue 3 
 
ongoing service charges, e-prescribing systems could pay for themselves 
in less than a year.46
 
[14]  Finally, e-prescribing offers a partial solution in the debate over tort 
reform and medical malpractice insurance.  Two percent of all adverse 
events lead to the filing of a medical malpractice claim, and the more 
severe the damage, the more likely a claim.47  E-prescribing could 
therefore eliminate up to 4,000 claims per year, easing the burden on 
health care providers, insurers, and the courts.48
 
The Business Impact of E-Prescribing 
 
[15]  Currently, physicians write 3.1 billion prescriptions annually, which 
is more than ten for each American.49  Many of these prescriptions are 
made in hospital, hospice, and institutional settings, although 
approximately 473,000 physicians work in private office settings and 
could make use of e-prescribing systems.50  Only five to eighteen percent 
of these physicians currently use e-prescribing, so a huge growth potential 
exists.51     
 
[16]  The start-up costs average approximately $2,000 per physician in the 
first year, and much less thereafter.52  This average accounts for 
implementation and software fees from the service provider, hardware 
such as the handheld device, wireless connectivity in the office, and data 
carrier fees.53  After initial installation, the physician must pay ongoing 
software and support fees to the e-prescribing service provider.54
 
                                                 
46 Terry, supra note 8. 
47 David A. Hyman, Medical Malpractice and the Tort System: What Do We Know and 
What (If Anything) Should We Do about It? 80 TEX. L. REV. 1639, 1643 (2002).
48 Id.; see EHEALTH INITIATIVE, supra note 34, at 28. 
49 Critser, supra note 1. 
50 Goedert, supra note 7. 
51 Terry, supra note 8. 
52 Id. 
53 Id. 
54 Id. 
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[17]  Despite these costs, health insurers, encouraged by the federal 
government, have begun to promote e-prescribing.55  For example, 
WellPoint has dedicated $40 million to provide hardware and a one-year 
subscription to either Allscripts or ZixCorp for its 19,000 network 
physicians, and both Blue Cross Blue Shield of Massachusetts and Tufts 
Health Plan offer a free, one-year subscription to PocketScript for 3,400 
high-prescribing physicians.56  
 
[18]  Health plans promote e-prescribing for one simple reason: the 
potential long-term savings far outweigh costs. Increased patient safety 
adds to a healthier bottom line.  Cutting the 190,000 hospitalizations that 
result annually from the 2.1 million adverse drug events could equal a 
savings of between $39 and $79 per employee per year in employer health 
plans.57  These numbers do not even address the savings for medical 
malpractice insurers because of the reduction in tort liability.  Although 
these figures do come from studies sponsored by the e-health industry and 
should be viewed guardedly, the truth is that more physicians are using e-
prescribing, more health plans are promoting e-prescribing, and more state 
laws are changing to accommodate e-prescribing. 
 
III. THE LEGAL ENVIRONMENT FOR E-PRESCRIBING 
 
A. DEA REGULATIONS 
 
[19]  The federal government regulates controlled substances through the 
Drug Enforcement Agency (DEA).58  Substances are listed as controlled 
because of their potential for abuse or addiction.59  Controlled substances 
are further classified by the DEA into five schedules, which are based on 
their medicinal value, potential for abuse, and safety or dependence 
liability.60  Schedule I substances (LSD, mescaline, marijuana) have no 
                                                 
55 Id. 
56 Id. 
57 EHEALTH INITIATIVE, supra note 34.  
58 See 21 C.F.R. §§ 1300 – 1316 (2005). 
59 21 U.S.C. § 802(6) (2000). 
60 Prescription Drugs, State Monitoring Programs May Help to Reduce Illegal 
Diversion: Testimony Before the Subcomm. on Health, Comm. on Energy and Commerce, 
108th Cong. 4 (2004) (statement of Marcia Crosse, Director, Public Health and Military 
Health Care Issues). 
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acceptable medical use and therefore may not be prescribed.61  Schedule II 
substances (Ritalin, Demerol, opiates) have medical uses but an extremely 
high potential for abuse.62  Prescriptions for Schedule II substances are the 
most restricted: they must be written (except for emergencies) and 
manually signed, the dosage is limited, and most of them cannot be 
refilled without a new prescription.63  Schedule III-V substances (anabolic 
steroids, anti-anxiety medications, narcotic cough syrups) have less 
potential for abuse.64  Prescriptions for these substances may be oral or 
written and manually signed, and they may be refilled for up to six 
months.65  Pharmacies must maintain records for all controlled substances 
dispensed and report these to the DEA on a regular basis.66   These federal 
regulations are the minimum standards that all states must follow.  
Although the DEA has no explicit regulations for electronic transmission, 
it currently treats e-prescriptions as oral prescriptions, so that Schedule III-
V substances may be transmitted electronically as long as the pharmacist 
verifies the prescription.67
 
B. CALIFORNIA 
 
[20]  California regulates e-prescribing and is one of the most e-friendly 
states because it has few specific limitations.  State regulations establish 
the requirements for the content of an e-prescription.68  California has no 
explicit technical requirements.  Instead, the state has an open-ended 
definition of e-prescriptions that allows for different and emerging 
technologies.69  The content requirements for controlled substances are in 
a different code section but essentially the same.70  California even has a 
code provision that would allow for the electronic transmission of 
                                                 
61 Id.; See 21 C.F.R. § 1308.11 (2005). 
62 Crosse, supra note 60; see § 13.08.12. 
63 Crosse, supra note 60; see § 1306.11. 
64 Crosse, supra note 60; see §§ 1308.13 – 1308.15. 
65 Crosse, supra note 60; see § 1306.21. 
66 Crosse, supra note 60; see §§ 1304.01 – 1304.33. 
67 Cohen, supra note 14. 
68 CAL. CODE REGS. tit. 16, § 1717.4 (Westlaw through 2005). 
69 Id.; see CAL. BUS. & PROF. CODE § 4040(a), (c) (West 2005) (defining an electronic 
data transmission prescription as “any prescription order, other than an electronic image 
transmission prescription, that is electronically transmitted from a licensed prescriber to a 
pharmacy”). 
70 CAL. HEALTH & SAFETY CODE § 11164(b)(1), (3) (West 2005). 
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Schedule II substances if and when the DEA regulations change.71  
Although state law allows pharmacists to substitute a generic for a 
prescribed brand-name drug, physicians may prevent such substitution on 
an e-prescription.72  Finally, out-of-state physicians may e-prescribe as 
long as they are licensed in their home state.73
 
C. TEXAS 
 
[21]  Texas also allows for e-prescribing, although its approach differs 
from California because Texas has more extensive and explicit 
regulations.  For example, Texas has thirteen different content 
requirements for e-prescriptions, including a statement that the 
prescription is “electronically transmitted to:” the recipient.74  The 
regulations for controlled substances are the same as for non-controlled.75  
Technical requirements are also listed, though no technical standards are 
specified.  Thus, for e-prescriptions, data must not be altered during 
transmission, and confidential patient information must be kept in 
accordance with federal and state law, but the means for achieving these 
two requirements are not given.76  Physicians may prevent generic 
substitution using e-prescribing.77  If the brand drug is medically 
necessary and the patient will receive Medicaid reimbursement, however, 
the physician must provide a written prescription order within thirty 
days.78  E-prescriptions from out-of-state physicians are acceptable, but 
for controlled substances, the out-of-state physician must be registered 
under the Texas Controlled Substances Act.79
 
 
 
 
                                                 
71 Id. § 11164.5(a). 
72 CAL. BUS. & PROF. CODE § 4073(a), (b) (West 2005). 
73 CAL. HEALTH & SAFETY CODE § 11150 (West 2005); CAL. BUS. & PROF. CODE § 4005 
(West 2005). 
74 22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (West 2005).
75 See id. § 291.34(b)(6)(B)(iii).
76 Id. § 291.34(b)(4)(A)(ii)(I)-(II). 
77 Id. § 309.3(c)(3)(A)-(C). 
78 Id. § 309.3(c)(3)(C). 
79 Id. § 291.34(b)(4)(C)(ii). 
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D. NEW YORK 
 
[22]  New York has the least progressive and most confusing e-
prescription regulations of the three states, although changes are pending.  
New York allows e-prescriptions, except for controlled substances, which 
are not allowed but not expressly prohibited.80  E-prescriptions must meet 
three technical requirements: an electronic signature; electronic encryption 
that will prevent access, alteration or use by an unauthorized person; and 
the ability to be reproduced in hard copy by the pharmacist.81  Further, the 
State Board of Pharmacy requires that e-prescribing systems have 
passwords, PINs, or other authentication of the prescriber.82  Regarding 
generic substitution, the prescription form must contain the words “THIS 
PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS 
PRESCRIBER WRITES ‘d a w’ IN THE BOX BELOW,” as well as meet 
other font, placement, and design requirements.83  Thus, the initials “d a 
w” (“dispense as written”) must be handwritten, which is of course 
impossible electronically.84  For Medicaid patients, the state further 
requires that the physician handwrite “brand medically necessary” or 
“brand necessary” in addition to “d a w.”85  Finally, the laws themselves 
are difficult to track and decipher.  Not only must an attorney consult 
various code titles, he or she must also refer to the Education statutes for 
the generic substitution requirement. 
 
[23]  Recently enacted legislation should make e-prescriptions more 
feasible in the near future.  New York has redefined “prescription” to 
include electronic prescriptions in the context of controlled substances.86  
Also, the state legislature has empowered the Commissioner of Health to 
                                                 
80 N.Y. COMP. CODES R. & REGS. tit. 8, § 63.6(a)(7)(i) (Westlaw through 2005); see N.Y. 
State Educ. Dep’t Office of the Professions, Electronic Transmittal of Prescriptions: 
Questions & Answers ¶ 14, http://www.op.nysed.gov/pharmqa.htm (last visited Nov. 7, 
2005). 
81 N. Y. COMP. CODES R. & REGS. tit. 8, § 63.6(a)(7)(ii)(a)-(c) (Westlaw through 2005). 
82 See N.Y. State Educ. Dep’t Office of the Professions, supra note 70 at ¶ 6. 
83 N.Y. EDUC. LAW § 6810(6)(a) (Consol. 2005). 
84 Id. 
85 N.Y. SOC. SERV. LAW § 361-a(9)(c) (Consol. 2005). 
86 N.Y. PUB. HEALTH LAW § 3302(31) (Consol. 2005). 
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create regulations regarding the use and transmission of e-prescriptions, 
including changes for Medicaid patients and out-of-state physicians.87
 
IV.  PROBLEMS AND CHALLENGES FOR E-PRESCRIBING 
[24]  As this sample of regulations demonstrates, much variation exists in 
the limits of e-prescribing in a given state.  Even where allowed, 
restrictions on form and content could cause an e-prescribing system that 
is valid in one state to be invalid in another.  Affecting all of this is 
uncertainty about the limits of e-prescribing controlled substances under 
federal regulations.  The following are the most common problems that 
attorneys in health care fields encounter. 
 
A. THE LACK OF FEDERAL STANDARDS 
The Questionable Permissibility of E-Prescribing for Controlled 
Substances 
 
[25]  Many commonly prescribed drugs are controlled substances: anti-
anxiety medications like Ativan, sleep aids like Ambien, the attention-
deficit disorder medication Ritalin, even cough syrup with codeine.88  For 
maximum efficiency, therefore, most health care professionals want e-
prescribing laws to allow for transmission of these substances.89  
Currently, the DEA, which has ultimate authority over all controlled 
substances, has promulgated no regulations regarding e-prescribing.  The 
DEA is still conducting a pilot program using digital signatures and Public 
Key Infrastructure (PKI) technology, which, although initiated in 1999, 
has yet to result in regulation.90
 
[26]  In the meantime, the DEA has chosen to treat e-prescriptions of 
controlled substances as oral orders.91  This position has not been posted 
                                                 
87 Id. §§ 21, 3308(5)-(6). 
88 21 C.F.R. § 1308.12 – 1308.15 (2005). 
89 See Cohen, supra note 14, at 10. 
90 DEA Diversion Control Program, Electronic Transmission of Prescriptions: Electronic 
Order Forms, http://www.deadiversion.usdoj.gov/ecomm/e_ordrs/ (last visited Jan. 16, 
2006). 
91 See SureScripts, SureScripts Partner & Provider Issue Bulletin #1: Transmission 
Methods Approved by the Drug Enforcement Administration (DEA) for Controlled 
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as official policy, which continues to be that e-prescriptions of controlled 
substances are not valid.92  Rather, a 2002 letter from the Chief of the 
Liaison and Policy Section of the Office of Diversion Control to a maker 
of e-prescribing systems explaining this position has circulated widely, so 
that many state regulators and health care professionals assume that e-
prescriptions for controlled substances are acceptable under federal law.93  
Marsha Cohen calls this informal law process a response to “regulatory 
ossification,” which basically means that the official lawmaking process 
has not kept pace with technology and industry.94  Although she favors e-
prescriptions, Cohen has criticized this response because it is outside of 
the notice and comment rulemaking process.95  Attorneys are put in the 
awkward position of giving legal advice that is correct based upon 
informal regulatory practice but that could become incorrect when the 
official regulations are approved—creating problems for all e-prescribing 
system providers, the health care professionals who use them, and even 
state officials who may need to rewrite their regulations. 
 
[27]  These federal regulations are also problematic because they merely 
represent the minimum standard, so most states can and do have their own 
controlled substances regulations that are more restrictive.96  Often, the 
regulations that flow from these state controlled substance statutes 
incorporate federal law.97  On a theoretical level, if the minimum 
standards are hazy and inexact, then states are building on a flawed 
foundation.  Further, and of more immediate concern for attorneys, is the 
inconsistency because of states’ differing interpretations of the minimal 
federal standard.98
                                                                                                                         
Substance Prescriptions, http://www.surescripts.com/DEADocument.doc (last visited Jan. 
16, 2006). This approach defeats one of the primary purposes of e-prescribing: efficiency.  
Oral orders for controlled substances must be personally verified by the pharmacist.  This 
means that upon receipt of an e-prescription, the pharmacist must call the physician’s 
office, even though the prescription has gone through an encrypted and password-
protected system. 
92 Cohen, supra note 14, at 10-11. 
93 Id. at 11. 
94 Cohen, supra note 14, at 11.  
95 Id. 
96 See, e.g., CAL. HEALTH & SAFETY CODE § 11164.5(a) (West 2005). 
97 Id. 
98 Compare 22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (allowing Schedule III-V 
substances to be transmitted electronically), with Black, supra note 13 (interpreting 
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Technical Inconsistency 
 
[28]  A second problem flowing from federal law relates to technology.  
Although current e-prescribing systems use Electronic Data Interchange 
(EDI), which features password-protected access and routes data through 
secure servers, the DEA’s test program incorporates Public Key 
Infrastructure (PKI) technology and digital signatures.99  With PKI, data is 
transmitted as complex computer algorithms, the recipient of the data must 
have both a public and a private “key” to decode the data, and third-party 
Certification Authorities issue and maintain the keys.100  Although PKI 
theoretically offers higher levels of security, privacy, authentication, and 
non-repudiation than EDI, practically these benefits are nullified by the 
high cost and difficulty in implementing and maintaining the technology.  
The result has been that the high expectations of PKI in the 1990s have 
failed to materialize in this decade.101   
 
[29]  If the DEA adopts this technical standard, then it would pre-empt 
laws like those in Texas.102  Although the California controlled substance 
e-prescribing statute includes language that accommodates changes in 
federal law, such changes would still require state approval of systems.103  
Either way, a change in the technical standard at the federal level would 
invalidate existing systems—costing e-prescribing providers and the 
health care professionals who have already adopted this technology much 
expense—and require a more expensive and difficult-to-use technology, 
without adding any appreciable benefit.  
 
                                                                                                                         
federal regulations as requiring electronically-generated prescriptions for Schedule III-V 
substances to be received via facsimile equipment and then orally verified with the 
prescriber). 
99 DEA Diversion Control Program, supra note 90. 
100 See Jan Lavorn, The Power of PKI, HEALTH MGMT. TECH. 20 (Dec. 2001). 
101 Even PKI providers and advocates acknowledge these limitations. See ANGELA 
KEITH, SANS INSTITUTE, COMMON ISSUES IN PKI IMPLEMENTATIONS—CLIMBING THE 
“SLOPE OF ENLIGHTENMENT” (2003), 
http://www.giac.org/practical/GSEC/Angela_Keith_GSEC.pdf. 
102 22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (treating e-prescriptions for controlled 
substances as oral prescriptions and therefore requiring no signature). 
103 CAL. HEALTH & SAFETY CODE § 11164.5(a) (West 2005). 
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[30]  A further federal complication is the requirement in the Medicare 
Modernization Act for a national technical standard by 2009, at least for 
transmission related to Medicare.104  Because the DEA is under the 
Department of Justice and Medicare is under the Department of Health 
and Human Services, there could be different, even conflicting, standards.  
Such pending changes, which are years from being finalized, create 
problems for health care attorneys who must make business and regulatory 
decisions now. 
 
B. STATE STATUTES & REGULATIONS 
 
A Time of Flux 
[31]  Perhaps the most important issue regarding state laws is how quickly 
they change.  Although these changes usually work to the benefit of e-
prescribing, attorneys who need to give advice based upon the current law 
face problems when a bill to overhaul e-prescribing is pending in the state 
legislature, or when a new version of the law will take effect in three 
months.  Consider that, when I first drafted this essay in January 2005, a 
change in New York laws to allow e-prescriptions for Medicaid recipients 
did not take effect until April.105  This ongoing flux is the norm in most 
states.  For example, the Texas requirement that generic substitution could 
only be prevented by handwriting “brand medically necessary” was 
changed in 2002.106  Also, the main California e-prescribing statute had 
slight numbering and textual changes that took effect January 1, 2005.107  
Finally, e-prescribing stakeholders in New York must sit and wait while 
the state promulgates regulations regarding controlled substances, 
Medicaid, and out-of-state prescribers.108\ 
 
Attention to Details 
 
[32]  Attorneys can easily spot major differences among state statutes and 
regulations, such as whether a state even allows e-prescriptions of 
                                                 
104 42 U.S.C.A. § 1395w-104(e) (Supp. 2005).
105 N.Y. COMP. CODES R. & REGS. tit. 18, § 505.3(b)(5) (2004). 
106 22 TEX. ADMIN. CODE § 309.3(c)(3)(A) (2004). 
107 CAL. HEALTH & SAFETY CODE § 11164 (West 2005). 
108 N.Y. PUB. HEALTH LAW §§ 21, 3308(5) (McKinney Supp. 2005); N.Y. EDUC. LAW § 
6810 (McKinney Supp. 2005). 
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controlled substances.  Often, however, more subtle legal requirements 
can escape notice.  For example, Texas requires that e-prescriptions 
contain a statement such as “electronically transmitted to:” and the name 
of the receiving pharmacy.109  Also, Texas requires the “electronic access 
number” of the pharmacy to which the prescription is transmitted, yet it 
does not define this term.110  It probably means the telephone number for 
faxes or computer address for EDI, but it may be something else, such as a 
state-provided account number.  Failure to include either one of these 
could invalidate the entire prescription, or at the least require time-wasting 
call-backs for verification.  Many states have variations on these 
requirements. 
 
Inconsistency with the Electronic Medium 
 
[33]  State laws are often incompatible with e-prescribing.  For example, 
because the state itself must pay the higher cost of brand-name drugs for 
Medicaid patients, states often have strict guidelines for how a physician 
can prevent substitution from the brand name drug to a generic equivalent.  
In Texas, a physician may prevent substitution via an e-prescription, but 
within thirty days he or she must provide a written prescription drug 
order.111  This requirement means a second prescription, thus negating the 
efficiency goal of e-prescribing. 
 
Inconsistency from State to State 
 
[34]  Several states have large metropolitan areas that spill into other 
states, such as Portland, St. Louis, New York City, and even Texarkana, 
which has a total population well in excess of 100,000.112  A person who 
lives in one state but works in the other could easily have a physician in 
one state but a pharmacy in the other.  A requirement that out-of-state 
physicians register under the Texas Controlled Substances Act for their 
controlled substance prescriptions to be valid is a nuisance.113  The fact 
                                                 
109 22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (2004). 
110 Id. § 291.34(b)(6)(B)(x). 
111 22 TEX. ADMIN. CODE § 309.3(c)(3)(A)-(C) (2004). 
112 Real Estate Center at Texas A&M, Texarkana Market Overview 2001: Population, 
2002, http://recenter.tamu.edu/mreports01/texarkana1.html (referencing the U.S. Census 
Bureau). 
113 22 TEX. ADMIN. CODE § 291.34(b)(4)(C)(ii) (2004). 
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that New Jersey requires an official state prescription form or oral 
verification for controlled substances, New York is currently promulgating 
regulations for controlled substances, and Connecticut requires state 
approval of e-prescribing systems while it promulgates new regulations is 
a legal migraine.114
 
V.  SOLUTIONS 
A. RECOMMENDATIONS 
[35]  The problems outlined in the previous section make addressing legal 
concerns, whether in giving advice to a practitioner or providing e-
prescribing services that will be valid in every state, incredibly difficult, 
but not impossible.  Some approaches can help ease the problems. 
 
Aim at Maximum Inclusion 
 
[36]  E-prescribing system providers can overcome the myriad of specific 
state requirements by incorporating as many as possible.  For example, the 
requirement in Texas that the prescription be marked as electronically 
transmitted appears in several other states’ regulations.115  Nothing in the 
regulations of states that do not have this requirement, however, forbids 
including the information.  Creating a system that makes this electronic 
transmission tag part of every prescription in every state will therefore 
ensure that such requirements are met. 
 
Track Legislative and Regulatory Changes 
 
[37]  Many state Boards of Pharmacy provide listserv notices or post 
online newsletters.116  These services give information about proposed 
                                                 
114 Compare N.J. ADMIN. CODE 13, § 13:35-7.4A(h) (2004), with N.Y. PUB. HEALTH 
LAW § 3308(5) (McKinney Supp. 2005), and CONN. GEN. STAT. ANN. § 20-614(d)(3) 
(West 2004 ). 
115 22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (2004); see, e.g., CONN. AGENCIES 
REGS. § 20-576-41 (2004).  
116 E.g., Bd. of Pharmacy, Join or Leave the Board of Pharmacy's E-Mail Notification 
List, http://www.pharmacy.ca.gov/subscriber_page.htm (last visited Jan. 16, 2006); Tex. 
State Bd. of Pharmacy, Newsletter, 
http://www.tsbp.state.tx.us/newsletter/NewsletterStart.htm (last visited Jan. 16, 2006). 
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legislative and regulatory changes, Board meeting times and places, and 
Q&A sections that clarify how certain regulations are defined and 
enforced.117  Also, regulatory officials in some states are excellent about 
returning phone calls and responding to emails.118  Finally, West’s 
KeyCite allows attorneys to select particular state statutes—and for larger 
states their regulations—for notification of changes.119  
 
Realize Where the Responsibility Lies 
[38]  Many states place the responsibility for ensuring the security and 
validity of an electronic prescription on the physician who transmits and / 
or the pharmacist who will fill and dispense the medication.120  Attorneys 
for health care providers should advise their clients of particular state 
restrictions or pending changes, while attorneys for e-prescribing system 
providers should strive for maximum functionality, trusting that health 
care professionals will follow state law.  In other words, the systems 
themselves should accommodate the most progressive state laws, and 
health care professionals should know the limit of their particular states’ 
regulations and use only those features which are appropriate. 
 
Drive the Regulations Rather than Being Driven 
 
[39]  Although changes in the law seem like a problem, the process of 
change may actually provide the best solution because it allows an 
opportunity for action.  State governments allow for comment on proposed 
regulatory changes.  For states with restrictive regulations, contact state 
legislators and the Board of Pharmacy directly.  Smaller states should 
realize that manufacturers are targeting larger states and adopt regulations 
that follow the trends in larger states.121  As discussed above, the trend in 
California, Texas and New York is toward more favorable e-prescribing 
laws.  
                                                 
117 E.g., Tx. State Bd. of Pharmacy, supra note 116. 
118 E.g., Telephone Interview with William Black, Legal Counsel, Wis. Dep’t of Regulation 
& Licensing (June 30, 2004). 
119 West, KeyCite, http://west.thomson.com/store/product.asp?product%5Fid=KeyCite 
(last visited Jan. 16, 2006). 
120 E.g., CAL. CODE REGS. tit. 16, § 1717.4(h) (Westlaw through 2005). 
121 Terry, supra note 8 (explaining that the company SureScipts is targeting fifteen large 
states).  
20 
Richmond Journal of Law & Technology Volume XII, Issue 3 
 
 
[40]  Driving the federal process may be most important.  Both the DEA 
and Medicare are promulgating standards, which state regulations will 
have to accommodate.  Both provide for comment and feedback, so 
attorneys and state regulators interested in e-prescribing should take 
advantage.122
VI.  CONCLUSION 
[41]  Because of improvements in efficiency and patient safety, e-
prescribing should continue to expand.  This expansion includes dozens of 
e-prescribing system providers, regulatory agencies from all fifty states, 
and every managed care and insurance provider.  It affects hundreds of 
thousands of health care professionals, and it will mean billions of dollars 
both in costs to implement and maintain and in savings from efficiency 
and safety.  The non-business side means reduced, or even eliminated, 
adverse drug reactions, which means fewer hospitalizations and deaths, 
which leads to better patient care.  Attorneys in health care fields will be 
challenged to stay abreast of a rapidly changing legal environment as state 
and federal laws develop to accommodate this technology. 
 
                                                 
122 Notice of Intent To Conduct Performance Verification Testing of Public Key 
Infrastructure Enabled Controlled Substance Orders, 67 Fed. Reg. 1,507 (Jan. 11, 2002); 
42 U.S.C.A. § 1395w-104(e)(4)(B) (Supp. 2005).
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